The EU bank will support Palma-based Sanifit in its work to develop cutting-edge solutions in biomedical research.
The venture debt operation is supported by the Investment Plan for Europe.
The European Investment Bank (EIB) is set to support the development of new treatments for progressive vascular calcification, an area of significant unmet medical need where there are currently no approved treatments. To this end, the EU bank will provide a €20 million loan to Spanish biopharmaceutical company Sanifit, which is developing novel treatments in two disease indications linked to calcification.
The EIB is advancing funds for this research, development and innovation (RDI) project by way of a venture debt operation with Investment Plan for Europe support, a financing instrument used by the EU bank to assist leading companies in innovative sectors. Since it was launched by the EIB under the Juncker Plan in 2016, this initiative has granted over €2 billion in financing for projects in areas such as robotics, artificial intelligence and biomedicine.
The EIB will provide Sanifit with long-term finance to drive the development of treatments for progressive vascular calcification disorders. The Company, founded as a spin-off out of the University of the Balearic Islands, has developed SNF472, a selective and potent inhibitor of hydroxyapatite (HAP) crystallisation, the final common pathway that leads to vascular calcification.
SNF472 is currently being investigated in a Phase 3 study for the treatment of calciphylaxis, a devastating rare disease where small blood vessels in skin and fat tissue are blocked due to severe calcification, leading to the death of approximately 55% of patients within the first year of diagnosis. A Phase 3 trial in a second indication, peripheral arterial disease, a major driver of morbidity and death in end-stage kidney disease patients, will launch in 2021.
EIB Vice-President Emma Navarro, responsible for the Bank's operations in Spain, highlighted the “positive impact of this operation on strengthening the competitiveness of the European biomedical industry, a sector requiring large-scale investment and tailored financing solutions. We are delighted to help a leading Spanish company to develop new medical treatments for vascular calcification that will have clear benefits for human health and wellbeing. This agreement underscores the EIB’s commitment to supporting European innovation, which is now more vital than ever to promoting economic recovery and job creation.”
Dr Joan Perelló, Chief Executive Officer of Sanifit, commented: “The support of the EIB represents a significant endorsement of our technology and its potential to help patients suffering from debilitating conditions related to progressive vascular calcification. This is an extremely exciting time for Sanifit as we progress SNF472 through the clinic, and this further investment will be invaluable as we gather the late stage data required for approval, and to deliver treatment options to patients in need.”
Sanifit is a clinical-stage biopharmaceutical company focused on treatments for vascular calcification disorders. The company is a spin-off from the University of the Balearic Islands and has offices in Spain and the U.S. The company’s lead asset, SNF472, has successfully completed a Phase 2 proof of concept study in calciphylaxis, and showed a significant reduction in progression of coronary calcification in a Phase 2b study among hemodialysis patients. A Phase 3 pivotal study in calciphylaxis is currently underway and a Phase 3 trial in Peripheral Arterial Disease in End Stage Kidney Disease patients will launch in 2021. Sanifit has raised approximately $130M, including a 2019 Series D round of $61.8M (€55.2M) in mid-2019. For more information please visit www.sanifit.com.
The European Investment Bank (EIB) has given Safran a 500 million euro credit line to finance its research into innovative propulsion systems for the next generation of single-aisle commercial airplanes. This marks a major step forward in Safran’s roadmap to achieve carbon-free air transport.
La Banque européenne d’investissement (BEI) et la Société Nationale des Autoroutes du Maroc (ADM), chargée de construire, exploiter et entretenir les autoroutes du Maroc, ont annoncé la conclusion d’un contrat de financement de 85 millions d’euros (environ 925 millions de dirhams) pour accélérer la digitalisation des infrastructures de transport autoroutières dans le pays. Ce projet contribuera à améliorer la fluidité du trafic à travers la digitalisation des systèmes de paiement et l’installation de systèmes de télépéage. Il contribuera à réduire les coûts et le temps de voyage et renforcera la sécurité des utilisateurs tout en offrant de nouveaux services personnalisables. Cette opération prévoit également le déploiement d’un système de suivi et de gestion du trafic qui donnera accès en temps réel aux conditions de circulation sur l’ensemble du réseau autoroutier.
S.E.M. Clément Mouamba, Premier ministre de la République du Congo, a souligné ce jour un nouvel engagement de la BEI visant à accélérer les investissements dans la transition numérique et à améliorer l’accès au financement pour l’ensemble des acteurs économiques du pays.